| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2023 | 96.49% | Cantor Fitzgerald | $54 → $52 | Maintains | Overweight |
| 10/12/2023 | 104.04% | Cantor Fitzgerald | → $54 | Reiterates | Overweight → Overweight |
| 09/27/2023 | 104.04% | Cantor Fitzgerald | → $54 | Reiterates | Overweight → Overweight |
| 08/22/2023 | -20.65% | Wells Fargo | → $21 | Initiates Coverage On | → Underweight |
| 08/16/2023 | 104.04% | Cantor Fitzgerald | → $54 | Reiterates | Overweight → Overweight |
| 08/10/2023 | 175.84% | HC Wainwright & Co. | → $73 | Reiterates | Buy → Buy |
| 08/09/2023 | 175.84% | HC Wainwright & Co. | → $73 | Reiterates | Buy → Buy |
| 06/12/2023 | 175.84% | HC Wainwright & Co. | → $73 | Reiterates | Buy → Buy |
| 05/31/2023 | 175.84% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 05/05/2023 | 104.04% | Cantor Fitzgerald | $55 → $54 | Maintains | Overweight |
| 05/05/2023 | 175.84% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 03/22/2023 | 175.84% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 03/01/2023 | 175.84% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 02/27/2023 | 175.84% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 11/11/2022 | 138.05% | Guggenheim | $68 → $63 | Maintains | Buy |
| 08/09/2022 | 141.83% | SVB Leerink | $68 → $64 | Maintains | Outperform |
| 07/01/2022 | 175.84% | HC Wainwright & Co. | $60 → $73 | Maintains | Buy |
| 09/17/2021 | 149.39% | Jefferies | → $66 | Initiates Coverage On | → Buy |
| 09/13/2021 | 126.71% | HC Wainwright & Co. | $54 → $60 | Maintains | Buy |
| 09/10/2021 | 156.94% | SVB Leerink | → $68 | Initiates Coverage On | → Outperform |
| 08/06/2021 | 104.04% | HC Wainwright & Co. | $50 → $54 | Maintains | Buy |
| 07/22/2021 | 149.39% | Guggenheim | → $66 | Initiates Coverage On | → Buy |
| 07/12/2021 | 88.93% | HC Wainwright & Co. | $36 → $50 | Maintains | Buy |
| 02/23/2021 | 36.03% | HC Wainwright & Co. | $25 → $36 | Maintains | Buy |
| 10/19/2020 | -5.54% | HC Wainwright & Co. | $16 → $25 | Maintains | Buy |
| 03/27/2020 | -39.54% | HC Wainwright & Co. | $19 → $16 | Reiterates | → Buy |
| 02/21/2020 | -69.77% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
What is the target price for Celldex Therapeutics (CLDX)?
The latest price target for Celldex Therapeutics (NASDAQ: CLDX) was reported by Cantor Fitzgerald on November 3, 2023. The analyst firm set a price target for $52.00 expecting CLDX to rise to within 12 months (a possible 96.49% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Celldex Therapeutics (CLDX)?
The latest analyst rating for Celldex Therapeutics (NASDAQ: CLDX) was provided by Cantor Fitzgerald, and Celldex Therapeutics maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Celldex Therapeutics (CLDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celldex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celldex Therapeutics was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.
Is the Analyst Rating Celldex Therapeutics (CLDX) correct?
While ratings are subjective and will change, the latest Celldex Therapeutics (CLDX) rating was a maintained with a price target of $54.00 to $52.00. The current price Celldex Therapeutics (CLDX) is trading at is $26.47, which is out of the analyst's predicted range.